Brind.

FDA approved ATEV for vascular trauma indication.

1 report, 1 independent Updated Aug 7

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA Humacyte (United States)

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Humacyte (United States)
company in Morrisville, United States

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 7GlobeNewswireHumacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025 DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage bi